ROIVW (Roivant Sciences) Other Financing: $197.55 Mil (TTM As of Mar. 2026)


ROIVW Roivant Sciences Ltd ROIVW
55 GF Score
Price $2.75
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Other Financing?

Roivant Sciences ROIVW -3.85% 55 Other Financing is $197.55 Mil as of Mar. 2026. GuruFocus rates ROIVW with a GF Score™ of 55/100. The stock has 7 warning signs investors should review.

Roivant Sciences's Other Financing for the three months ended in Mar. 2026 was $42.43 Mil.

Roivant Sciences's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $197.55 Mil.

Roivant Sciences Other Financing Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Other Financing Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial 291.98 -10.00 11.51 13.41 260.13

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.29 20.53 0.00 134.59 42.43
ROIVW
55GF Score
Roivant Sciences Ltd ROIVW
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $197.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $197.55 Mil mean?
Roivant Sciences (ROIVW) has a Other Financing of $197.55 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Roivant Sciences and its competitors.
Is Roivant Sciences' Other Financing too high?
Roivant Sciences' current Other Financing is $197.55 Mil. Overall, Roivant Sciences has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Other Financing compare to INSM and INCY?
Roivant Sciences' Other Financing of $197.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Roivant Sciences and its competitors. Roivant Sciences's current Other Financing is $197.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Roivant Sciences (ROIVW) has a current Other Financing of $197.55 Mil. The current Other Financing is $197.55 Mil. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Roivant Sciences (ROIVW), the current Other Financing is $197.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIVW

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price